Perspective Therapeutics Initiates Phase 1/2a Clinical Trials for Two Targeted Alpha Therapy Oncology Product Candidates
June 21, 2023 08:00 ET
|
Perspective Therapeutics, Inc.
VMT-α-NET for neuroendocrine cancers and VMT01 for melanoma are both entering therapeutic trials under IND at leading US institutions. First melanoma patient screened and imaged with...
Perspective Therapeutics’ Cesium-131 to be Featured in Presentations at the 2023 American Brachytherapy Society’s Annual Meeting
June 16, 2023 08:00 ET
|
Perspective Therapeutics, Inc.
RICHLAND, Wash & CORALVILLE, IOWA, June 16, 2023 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (NYSE AMERICAN: CATX), a precision oncology company developing alpha-particle therapies and...
Perspective Therapeutics to Present at the 2023 Annual Society for Nuclear Medicine and Molecular Imaging Conference
June 08, 2023 08:00 ET
|
Perspective Therapeutics, Inc.
RICHLAND, WASHINGTON & CORALVILLE, IOWA, June 08, 2023 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or “the Company”) (NYSE AMERICAN: CATX), a precision oncology company...
Perspective Therapeutics to Present at the 2023 International Symposium on Radiopharmaceutical Sciences (iSRS)
May 24, 2023 08:10 ET
|
Perspective Therapeutics, Inc.
Three poster presentations from Perspective Therapeutics’ scientists and collaborators explore combinations of immunotherapy and targeted alpha-particle therapy in a malignant melanoma model, 203Pb...
Perspective Therapeutics Reports First Quarter Fiscal 2023 Results
May 15, 2023 20:22 ET
|
Perspective Therapeutics, Inc.
Additional CDMO capabilities added to increase availability of clinical trial product in the USPhase I/IIa studies are initiating in the first half of 2023 for VMT-α-NET for neuroendocrine tumors and...
Perspective Therapeutics Announces Changes to the Board of Directors
May 15, 2023 16:49 ET
|
Perspective Therapeutics, Inc.
Heidi Henson was appointed to the Board of Directors and named Audit Committee Chair taking over from Rob Williamson, III, who will continue to serve as a member of the CommitteeMichael McCormick...
Perspective Therapeutics Expands Management Team And Names Andrew Bright as Executive Vice-President of Brachytherapy
April 03, 2023 08:15 ET
|
Perspective Therapeutics, Inc.
The appointment advances Perspective Therapeutics’ journey to become a global leader in the manufacturing and distribution of therapeutic Cesium-131 brachytherapy radioisotope seeds designed for the...
Perspective Therapeutics Announces the Awarding of a $1 million Collaborative Grant to King’s College London to Support Radiobiology Research of Alpha Particle Therapy for Cancer
March 08, 2023 07:30 ET
|
Perspective Therapeutics, Inc.
The grant from the Medical Research Council (MRC) of the United Kingdom (part of UK Innovation and Research; UKRI) is supporting preclinical in vitro and in vivo studies of [212Pb]VMT-α-NET for...
Initial Results From First Patient Dosed With Perspective Therapeutics’ Lead Drug VMT-α-NET Presented at The Treatment of Neuroendocrine Disorders at the 2023 PET/RTRC Annual Workshop Scientific Session
February 22, 2023 17:03 ET
|
Perspective Therapeutics, Inc.
RICHLAND, Wash. & CORALVILLE, Iowa, Feb. 22, 2023 (GLOBE NEWSWIRE) -- Perspective, Therapeutics, Inc. (formerly known as “Isoray, Inc.”) (NYSE AMERICAN: CATX), a precision oncology company...
Perspective Therapeutics (formerly known as Isoray, Inc.) Announces Financial Results for the Quarter ended December 31, 2022
February 16, 2023 16:05 ET
|
Perspective Therapeutics, Inc.
RICHLAND, Wash. and CORALVILLE, Iowa, Feb. 16, 2023 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (formerly known as Isoray, Inc.) (NYSE AMERICAN: ISR), a precision oncology company developing...